Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MANGOCEUTICALS, INC. (MGRX)

Mangoceuticals' MangoRx IP sells 25% stake to two investors for $2.5 million

Neutral Impact 3 of 5 financing Written later

Mangoceuticals' subsidiary MangoRx IP Holdings, which holds the patent portfolio behind its MGX-0024 antiviral technology, entered into subscription agreements on September 30, 2026 with two accredited investors for a combined 25% membership interest at $2.5 million. The company received $1.75 million at the initial closing, and the remaining $750,000 is due by November 28, 2026. The company states that no Mangoceuticals common stock, warrants or other parent-company securities were issued, so the deal does not increase the parent's outstanding shares.

Key points

  • Two accredited investors agreed to buy a combined 25% membership interest in MangoRx IP for $2.5 million.
  • The company has received $1.75 million so far; the second payment of $750,000 is due by November 28, 2026.
  • No shares of Mangoceuticals common stock, warrants or other parent-company securities were issued, according to the company.
  • Proceeds are to fund commercialization of the MangoRx IP patent portfolio; the filing says the deal was made without a public offering.

The filing

CompanyMANGOCEUTICALS, INC. (MGRX)
Form8-K, current report
Filed with the SECOct 1, 2026, 3:50 PM ET
Accession number0001493152-26-045341

Items reported: 1.01 Material Definitive Agreement2.01 Acquisition or Disposition Completed3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.